Related Experiment Video

Updated: Jan 16, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

8.1K

ApoC3 Attenuates Platelet Activation Through GPIIb/IIIa Receptor Interaction

Michael Holzer1,2, Eva Gruden1,3, Sanja Curcic4

  • 1Otto-Loewi Research Center, Division of Pharmacology, Medical University of Graz, 8010 Graz, Austria.

Cells
|September 26, 2025
PubMed

Insights

Apolipoprotein C3 (apoC3) significantly inhibits platelet activation and aggregation, revealing a new role in regulating blood clot formation and vascular health. This finding suggests apoC3 as a potential therapeutic target for thrombotic disorders.

Area of Science:

  • Biochemistry
  • Hematology
  • Cardiovascular Research

Background:

  • Apolipoprotein C3 (apoC3) is crucial for triglyceride metabolism and cardiovascular disease risk.
  • The full physiological functions of apoC3, beyond lipid metabolism, remain largely unexplored.
  • Understanding apoC3's role in hemostasis is vital for developing new therapeutic strategies.

Purpose of the Study:

  • To investigate the role of apolipoprotein C3 (apoC3) in platelet function.
  • To determine the impact of apoC3 on thrombus formation and platelet activation.
  • To elucidate the mechanisms underlying apoC3's interaction with platelets.

Main Methods:

  • Assessing apoC3's effect on platelet activation induced by ADP and collagen.
  • Measuring platelet aggregation in serum with and without apoC3.
  • Quantifying apoC3 binding to platelets and its effect on GPIIb/IIIa activation and P-selectin expression.

Main Results:

  • Human apoC3 rapidly inhibited platelet activation at concentrations from 0.1-10 µg/mL.
  • Platelet aggregation increased by over 25% when endogenous apoC3 was depleted from serum.
  • ApoC3 binding to platelets reduced GPIIb/IIIa activation and P-selectin expression, with binding enhanced by ADP stimulation via GPIIb/IIIa.

Conclusions:

  • Apolipoprotein C3 plays a novel inhibitory role in platelet function and thrombus formation.
  • ApoC3 exhibits an endogenous regulatory function in platelet aggregation.
  • These findings highlight a new link between apoC3 and vascular homeostasis, with implications for thrombotic risk.

Keywords:
GPIIb/IIIaapoC3apolipoproteinslipoprotein/receptorsplateletsvascular biology

More Related Videos

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

18.6K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.4K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
462
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.9K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
245